Literature DB >> 342157

The effect of cyclophosphamide on an ocular immune response. I. Primary response.

J M Hall, S Ohno, J F Pribnow.   

Abstract

The ocular inflammation and antibody production that follow intravitreal injection of rabbit eyes with bovine gamma globulin were suppressed by treatment with Cytoxan by the intramuscular (i.m.) route. The drug suppressed PFC responses of uveal tract and corneal cells when it was administered, beginning as late as 5 days after immunization, if treatment was continued until day 12 or 13. Short-term treatments and treatment with smaller Cytoxan doses were less effective. We noted a good correlation between the presence or absence of ocular inflammation, suppression of ocular PFC responses and depression of serum, aqueous humour and vitreous humour antibody titres. In some treatment groups ocular antibody production seemed to be completely suppressed, while in others antibody production was significantly delayed.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 342157      PMCID: PMC1541121     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  20 in total

1.  Immunosuppression with cyclophosphamide: effect on antibody plaque-forming spleen cells and on hemolytic antibodies production.

Authors:  E Bohunická; I Koza; S Kuzela; V Krempaský; V Ujházy
Journal:  Neoplasma       Date:  1972       Impact factor: 2.575

2.  Combination drug treatment in immunosuppression. Effect of azathioprine, cyclophosphamide, and methylprednisolone on rabbit renal allografts.

Authors:  E A Friedman; A Ueno; M M Beyr; A D Nicastri
Journal:  Transplantation       Date:  1973-06       Impact factor: 4.939

3.  Suppression of cell-mediated immunity by cyclophosphamide: its independence of concomitant B cell response.

Authors:  A M Jokipii; L Jokipii
Journal:  Cell Immunol       Date:  1973-12       Impact factor: 4.868

4.  Responses of the reticuloendothelial system of the rabbit to intraocular injections of foreign protein.

Authors:  J M Hall; J F Pribnow
Journal:  Cell Immunol       Date:  1972-11       Impact factor: 4.868

5.  Specificity of antibody formation after intravitreal immunization with bovine gamma globulin and ovalbumin. I. Primary response.

Authors:  J M Hall
Journal:  Invest Ophthalmol       Date:  1971-10

6.  Reversal of immunological tolerance by cyclophosphamide through inhibition of suppressor cell activity.

Authors:  L Polak; J L Turk
Journal:  Nature       Date:  1974-06-14       Impact factor: 49.962

7.  Correlation between ocular inflammation and antibody production. II. Hemolytic plaque formation by cells of the uveal tract.

Authors:  J M Hall; G R O'Connor
Journal:  J Immunol       Date:  1970-02       Impact factor: 5.422

8.  Suppression of thyroid lesions in rabbits by treatment with cyclophosphamide after the induction of thyroiditis.

Authors:  R M Nakamura; W O Weigle
Journal:  Clin Exp Immunol       Date:  1970-10       Impact factor: 4.330

9.  Cyclophosphamide-induced tolerance to equine globulin and to equine-anti-mouse-thymocyte globulin in adult mice. I. Studies on antigen and drug requirements.

Authors:  G D Stockman; J J Trentin
Journal:  J Immunol       Date:  1972-01       Impact factor: 5.422

10.  Potentiation of T-cell-mediated immunity by selective suppression of antibody formation with cyclophosphamide.

Authors:  P H Lagrange; G B Mackaness; T E Miller
Journal:  J Exp Med       Date:  1974-06-01       Impact factor: 14.307

View more
  2 in total

Review 1.  Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches.

Authors:  Rita Diehl; Fabienne Ferrara; Claudia Müller; Antje Y Dreyer; Damian D McLeod; Stephan Fricke; Johannes Boltze
Journal:  Cell Mol Immunol       Date:  2016-10-10       Impact factor: 11.530

2.  SBT (Composed of Panax ginseng and Aconitum carmichaeli) and Stigmasterol Enhances Nitric Oxide Production and Exerts Curative Properties as a Potential Anti-Oxidant and Immunity-Enhancing Agent.

Authors:  Na-Ra Han; Kyeoung-Cheol Kim; Ju-Sung Kim; Hi-Joon Park; Seong-Gyu Ko; Phil-Dong Moon
Journal:  Antioxidants (Basel)       Date:  2022-01-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.